Showing 1 to 1 of 1 results
welt.de
🌐 75% Global Worthiness


Donanemab Approved for Early-Stage Alzheimer's with Stricter Guidelines
Donanemab, a new Alzheimer's drug, received conditional approval in Europe, slowing disease progression by up to six months in early stages for patients with mild cognitive impairment and only one copy of the ApoE4 gene, but with risks of brain swelling and bleeding.
Donanemab Approved for Early-Stage Alzheimer's with Stricter Guidelines
Donanemab, a new Alzheimer's drug, received conditional approval in Europe, slowing disease progression by up to six months in early stages for patients with mild cognitive impairment and only one copy of the ApoE4 gene, but with risks of brain swelling and bleeding.
Progress
48% Bias Score
Good Health and Well-being
Showing 1 to 1 of 1 results